Responses
Therapeutics
Randomised controlled trial
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux
Compose a Response to This Article
Other responses
No responses have been published for this article.